{"id":56399,"date":"2026-02-05T20:20:49","date_gmt":"2026-02-05T12:20:49","guid":{"rendered":"https:\/\/flcube.com\/?p=56399"},"modified":"2026-02-05T20:20:50","modified_gmt":"2026-02-05T12:20:50","slug":"astrazeneca-saphnelo-faces-fda-setback-with-complete-response-letter","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56399","title":{"rendered":"AstraZeneca Saphnelo Faces FDA Setback with Complete Response Letter"},"content":{"rendered":"\n

AstraZeneca<\/strong> (AZ, NASDAQ:\u202fAZN<\/a>) announced it has received a Complete Response Letter (CRL)<\/strong> from the U.S. Food and Drug Administration (FDA)<\/strong> regarding the Biologics License Application (BLA) for Saphnelo (anifrolumab)<\/strong> for subcutaneous (SC) administration in adult patients with systemic lupus erythematosus (SLE)<\/strong>. The intravenous (IV) formulation remains commercially available.<\/p>\n\n\n\n

Regulatory Status & Clinical Background<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>AstraZeneca (NASDAQ:\u202fAZN)<\/td><\/tr>
Drug<\/strong><\/td>Saphnelo (anifrolumab)<\/td><\/tr>
Formulation<\/strong><\/td>Subcutaneous (SC)<\/td><\/tr>
Indication<\/strong><\/td>Systemic lupus erythematosus (SLE)<\/td><\/tr>
Regulatory Action<\/strong><\/td>Complete Response Letter (CRL)<\/td><\/tr>
IV Status<\/strong><\/td>Commercially available<\/td><\/tr>
Clinical Basis<\/strong><\/td>Phase 3 TULIP-SC trial<\/td><\/tr>
Trial Results<\/strong><\/td>Safety profile consistent with IV infusion<\/td><\/tr>
Next Steps<\/strong><\/td>AstraZeneca has responded to CRL; FDA decision expected H1 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Strategic Implications<\/h2>\n\n\n\n